Density and entropy of immune cells within the tumor microenvironment of primary tumors and matched brain metastases
- PMID: 39972401
- PMCID: PMC11837646
- DOI: 10.1186/s40478-025-01939-8
Density and entropy of immune cells within the tumor microenvironment of primary tumors and matched brain metastases
Abstract
Background: Tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) have increasingly been reported to impact the brain metastatic process of solid tumors. However, data on intra-individual differences between primary tumor and brain metastasis (BM), as well as their correlation with clinical outcome parameters, is scarce.
Methods: We retrospectively identified patients who received resection of the primary tumor and BM between 01/1990 and 10/2022. Density quantification of TAMs (CD68+, CD163+) and TILs (CD3+, CD8+, CD45RO+, FOXP3+) was performed by immunohistochemical staining of matched tumor tissue samples. Images were processed with QuPath software and heterogeneity of generated heatmaps was measured by Shannon Entropy. Time-to-BM (TTBM) was defined as the time from diagnosis of the primary tumor until the first diagnosis of BM.
Results: In total, 104 patients (46.2% female; median age 57.3 years at BM diagnosis) were included: 78/104 (75%) non-small cell lung cancer, 18/104 (17%) breast cancer, 8/104 (8%) renal cell carcinomas. Densities of CD3+ (p < 0.001) and CD8+-TILs (p < 0.001) were higher in primary tumor samples, while CD68+ (p = 0.035) and CD163+-TAM densities (p < 0.001) were higher in the matched BM. Higher CD3+, CD8+-TILs and CD163+-TAMs densities in primary tumors were associated with shorter TTBM (p = 0.005, p = 0.015 and p = 0.006, respectively). Higher entropies of CD3+ (p < 0.001) and FOXP3+ (p = 0.011) TILs were observed in primary tumors compared to BM. Longer TTBM was associated with higher entropy of FOXP3+ TILs (p = 0.024) and lower entropy in CD163+ TAMs (p = 0.039). No significant associations of immune cell densities or entropies with OS after BM diagnosis were found.
Discussion: By utilizing a unique cohort of matched primary tumor and BM tissue samples, we could demonstrate higher TIL densities in primary tumors and higher TAM densities in BM, respectively. Higher cell densities of CD3+, CD8+-TILs and CD163+-TAMs in primary tumors were associated with shorter TTBM, while a larger difference between CD3+ and CD8+ densities between primary tumor and BM was associated with longer TTBM. These findings highlight the potential of targeting TAMs as a therapeutic strategy to mitigate the development of brain metastases.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: This study was approved by the Ethics Committees of the Medical University of Vienna (approval no. 1692/2022, 1895/2022). Consent for publication: Not applicable. Competing interests: M.J.M. received research funding from Bristol-Myers Squibb and travel support from Pierre Fabre. A.S.B. received research support from Daiichi Sankyo, Roche, and honoraria for lectures, consultation or advisory board participation from Roche, Bristol-Meyers Squibb, Merck, Daiichi Sankyo as well as travel support from Roche, Amgen and AbbVie. Z.S. is a former employee of Boehringer Ingelheim and Turbine AI. M.P. received honoraria for lectures, consultation, or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen. J.N.K declares consulting services for Bioptimus, France; Owkin, France; DoMore Diagnostics, Norway; Panakeia, UK; AstraZeneca, UK; Scailyte, Switzerland; Mindpeak, Germany; and MultiplexDx, Slovakia. Furthermore he holds shares in StratifAI GmbH, Germany, has received a research grant by GSK, and has received honoraria by AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Janssen, MSD, BMS, Roche, Pfizer and Fresenius.
Figures




Similar articles
-
Immune Profiling of Incidental NSCLC Patients: Comparison Between Tumor Sections and TMA Cores.Appl Immunohistochem Mol Morphol. 2025 Jul 1;33(4):218-229. doi: 10.1097/PAI.0000000000001266. Epub 2025 Jun 2. Appl Immunohistochem Mol Morphol. 2025. PMID: 40452253
-
Nomograms for stratified prognosis prediction of gastric cancer by integrating programmed death ligand 1 and tumor-infiltrating immune cells including CD4+/CD8+ TILs and CD163+ TAMs.Front Oncol. 2025 Jun 25;15:1530054. doi: 10.3389/fonc.2025.1530054. eCollection 2025. Front Oncol. 2025. PMID: 40636693 Free PMC article.
-
Phenotypic and Spatial Characterization of Tumor-Associated Macrophages in Non-Metastatic Seminoma: Association with Local Tumor Progression.Med Sci (Basel). 2025 Aug 14;13(3):129. doi: 10.3390/medsci13030129. Med Sci (Basel). 2025. PMID: 40843751 Free PMC article.
-
Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis.BMC Cancer. 2016 Aug 26;16(1):687. doi: 10.1186/s12885-016-2732-0. BMC Cancer. 2016. PMID: 27566250 Free PMC article.
-
Prognostic significance of tumor-infiltrating lymphocytes and macrophages in nasopharyngeal carcinoma: a systematic review and meta-analysis.Eur Arch Otorhinolaryngol. 2022 Jan;279(1):25-35. doi: 10.1007/s00405-021-06879-2. Epub 2021 May 24. Eur Arch Otorhinolaryngol. 2022. PMID: 34027599
References
-
- Bejarano L, Jordāo MJC, Joyce JA (2021) Therapeutic targeting of the tumor microenvironment. Cancer Discov 11:933–959 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials